Literature DB >> 14716843

Effects of Zhaoyangwan on chronic hepatitis B and posthepatic cirrhosis.

Cui-Ping Zhang1, Zi-Bin Tian, Xi-Shuang Liu, Qing-Xi Zhao, Jun Wu, Yong-Xin Liang.   

Abstract

AIM: To study the therapeutic effects of zhaoyangwan (ZYW) on chronic hepatitis B and hepatic cirrhosis and the anti-virus, anti-fibrosis and immunoregulatory mechanisms of ZYW.
METHODS: Fifty cases of chronic hepatitis B and posthepatic cirrhosis with positive serum HBsAg, HBeAg, anti-Hbc and HBV-DNA were divided randomly and single-blindly into the treatment group (treated with ZYW) and the control group (treated with interferon). After 3 month treatment, the effects of the treatment group and the control group were evaluated.
RESULTS: The serum ALT normalization was 83.3% (30/36) in the treatment group and 85.7% (12/14) in the control group, with no significant difference (chi2=0.043, P>0.05). After the course, the negative expression rates of the serum HBV-DNA and HBeAg were 44.4% (16/36) and 50% (18/36) in the treatment group, and 50% (7/14) and 50% (7/14) in the control group, respectively, with no significant difference (chi2=0.125, chi2=0.00, both P>0.05). Negative HBsAg and positive HBsAb appeared in 4 cases of the treatment group and 1 case of the control group. Serum anti-HBc turned negative in 6 cases of the treatment group and 1 case of the control group, respectively. After the ZYW treatment, serum CD3+, CD4+, CD8+, CD4+/CD8+ and NK cell activation were significantly increased. Only serum CD3+ and NK cell activation were significantly increased in the control group with a significant difference between the two groups. The serum C4, C1q, C3, B and C9 were significantly increased in the treatment group. In the control group only the serum C4 was increased. The concentration of serum interferon had no change after treatment with ZYW, while it was significantly increased in the control group after treatment with interferon. The ultrastructure of the liver restored, which helped effectively to reduce the degeneration and necrosis of hepatic cells,infiltration of inflammatory cells and hepatic cirrhosis.
CONCLUSION: ZYW is a pure Chinese herbal medicine. It can exert potent therapeutic effects on chronic hepatitis B and posthepatic cirrhosis. ZYW has similar therapeutic effects to those of interferon. It is cheap and easily administered with no obvious side-effects. It can be widely used in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716843      PMCID: PMC4717024          DOI: 10.3748/wjg.v10.i2.295

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Treatment of chronic hepatitis B: a need for consensus.

Authors:  Y F Liaw
Journal:  J Gastroenterol Hepatol       Date:  1999-01       Impact factor: 4.029

2.  Combined interferon and lamivudine therapy: is this the treatment of choice for patients with chronic hepatitis B virus infection?

Authors:  N A Terrault
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

Review 3.  Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention.

Authors:  Y Shiratori; H Yoshida; M Omata
Journal:  Expert Rev Anticancer Ther       Date:  2001-08       Impact factor: 4.512

4.  [Specific cellular and humoral immune responses induced by intramuscular injection of DNA vaccine containing HBV HBsAg gene in mice].

Authors:  S Liu; D Tan; C Li
Journal:  Hunan Yi Ke Da Xue Xue Bao       Date:  1999

Review 5.  Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C.

Authors:  N M Valiante; A D'Andrea; S Crotta; F Lechner; P Klenerman; S Nuti; A Wack; S Abrignani
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

6.  Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms.

Authors:  G J Webster; S Reignat; M K Maini; S A Whalley; G S Ogg; A King; D Brown; P L Amlot; R Williams; D Vergani; G M Dusheiko; A Bertoletti
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

7.  Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

Authors:  G K Lau; M Tsiang; J Hou; S Yuen; W F Carman; L Zhang; C S Gibbs; S Lam
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

Review 8.  Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives.

Authors:  M Okuno; S Kojima; H Moriwaki
Journal:  J Gastroenterol Hepatol       Date:  2001-12       Impact factor: 4.029

9.  Comparison of manganese superoxide dismutase precursor induction ability in human hepatoma cells with or without hepatitis B virus DNA insertion.

Authors:  V Hajnická; P Proost; J Kazár; N Fuchsberger
Journal:  Acta Virol       Date:  2000-12       Impact factor: 1.162

10.  Steroid hormone receptor in pleural solitary fibrous tumours and CD34+ progenitor stromal cells.

Authors:  Massimo Bongiovanni; Laura Viberti; Carla Pecchioni; Mauro Papotti; Renè Thonhofer; Helmut Hans Popper; Anna Sapino
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

View more
  4 in total

1.  Value of portal hemodynamics and hypersplenism in cirrhosis staging.

Authors:  Bao-Min Shi; Xiu-Yan Wang; Qing-Ling Mu; Tai-Huang Wu; Jian Xu
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

2.  Extract from Phyllanthus urinaria L. inhibits hepatitis B virus replication and expression in hepatitis B virus transfection model in vitro.

Authors:  Ying Wu; Ying Lu; Shu-yu Li; Yue-han Song; Yu Hao; Qian Wang
Journal:  Chin J Integr Med       Date:  2015-04-13       Impact factor: 1.978

3.  Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation.

Authors:  Tadeusz-Wojciech Lapinski; Robert Flisiak; Jerzy Jaroszewicz; Malgorzata Michalewicz; Oksana Kowalczuk
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

Review 4.  Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders.

Authors:  Rolf Teschke; Albrecht Wolff; Christian Frenzel; Axel Eickhoff; Johannes Schulze
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.